தனிப்பயனாக்கப்பட்டது ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Common anti-coagulant drug could treat emerging variants of SARS-CoV-2 QUT PhD researcher Zachariah Schuurs said the research team had identified a new binding site on the SARS-CoV-2 spike protein. Binding of the CoV-2 spike protein to heparan sulphate (HS) on cell surfaces is generally the first step in a cascade of interactions the virus needs to initiate an infection and enter the cell. Most research has focused on understanding how HS interacts on the receptor-binding domain (RBD) and furin cleavage site of the SARS-CoV-2 virus s spike protein, as these typically bind different types of drugs, vaccines and antibodies. We have identified a novel binding site on the N-terminal domain (NTD), a different area of the virus s spike that facilitates the binding of HS. This helps to better understand how the virus infects cells. The NTD is also a part of the spike protein that frequently mutates.

South africaZachariah schuursSneha gandhiEmily hendersonUniversity of queensland glycochemistryPersonalised healthCentre for genomicsZucero pharmaceuticalsCurtin university immunologyStructural biotechnology journalCurtin universityநேஹா காந்திஎமிலி ஹென்டர்சன்தனிப்பயனாக்கப்பட்டது ஆரோக்கியம்மையம் க்கு மரபியல்கட்டமைப்பு உயிரி தொழில்நுட்பவியல் இதழ்